Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 6, 2007, Pages 329-341

  Hurwitz, Selwyn J ^a   Asif, Ghazia ^a   Schinazi, Raymond F ^a  

^a NONE

Author keywords

Antiviral agents; HIV dynamics; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; LAMIVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MONTE CARLO METHOD; POPULATION MODEL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; TREATMENT OUTCOME; VIROLOGY;

EID: 41349110928     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800605     Document Type: Article

References (54)

1. Acosta EP, Henry K, Baken L, Page LM & Fletcher CV (1999) Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
2. Austin DJ, White NJ & Anderson RM (1998) The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. Journal of Theoretical Biology 194:313-339.
3. Balimane PV & Sinko PJ (1999) Involvement of multiple transporters in the oral absorption of nucleoside analogues. Advanced Drug Delivery Reviews 39:183-209.
4. Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, Wilkins EG, Williams O, Breckenridge AM & Back DJ (1996) The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10: 1361-1367.
5. Bonhoeffer S, May RM, Shaw GM & Nowak MA (1997) Virus dynamics and drug therapy. Proceedings of the National Academy of Sciences of the United States of America 94:6971-6976.
6. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 283:381-390.
7. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA & Haase AT (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-964.
8. Cloyd MW, Chen JJ & Wang I (2000) How does HIV cause AIDS? The homing theory. Molecular Medicine Today 6:108-111.
9. Daar ES & Richman DD (2005) Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Research and Human Retroviruses 21:343-357.
10. Dixit NM & Perelson AS (2004) Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. Journal of Theoretical Biology 226:95-109.
11. + cells per cubic millimeter. North American HIV Working Party. New England Journal of Medicine 333:1662-1669.
12. Fletcher CV (1999) Pharmacologic considerations for therapeutic success with antiretroviral agents. The Annals of Pharmacotherapy 33:989-995.
13. Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C & Kline MW (2000) Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents & Chemotherapy 44:1029-1034.
14. Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Gunthard HF & Bonhoeffer S (2006) HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. Journal of Medical Virology 78:1141-1146.
15. Gabrielsson J & Weiner D (2000) Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. 3rd edn. Stokholm, Sweden: Swedish Pharmaceutical Press; pp. 438-443.
16. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS & Richman DD (2003) Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antiviral Therapy 8:489-506.
17. Godfrey KR, Chapman MJ & Vajda S (1994) Identifiability and indistinguishability of nonlinear pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutics 22:229-251.
18. Guerguiva I, Nestorov I & Aarons L (2005) Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. Pharmaceutical Research 22:1614-1626.
19. Hale M, Gillespie W, Gupta S, Tuk B & Holford N (1996) Clinical trial simulation: streamlining your drug development process. Applied Clinical Trials 5:35-40.
20. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG & Volberding PA (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 296:827-843.
21. Holian A, Deutsch CJ, Holian SK, Daniele RP & Wilson DF (1979) Lymphocyte response to phytohemagglutinin: intracellular volume and intracellular [K+]. Journal of Cellular Physiology 98:137-44.
22. Huang Y, Rosenkranz SL & Wu H (2003) Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Mathematical Biosciences 184:165-186.
23. Hurwitz SJ & Schinazi RF (2002) Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Research 56:115-127.
24. Ickovics JR & Meisler AW (1997) Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Journal of Clinical Epidemiology 50:385-391.
25. Lesko LJ, Rowland M, Peck CC & Blaschke TF (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Journal of Clinical Pharmacology 40:803-814.
26. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, Leduc D, Perrin L, & Hirschel B (1997) Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 11:F95-F99.
27. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM & Mellors JW (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogens 3:e46.
28. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS & Ho DD (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. Journal of Virology 77:5037-5038.
29. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, Hellerstein MK & Ho DD (2001) Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. Journal of Experimental Medicine 194:1277-1287.
30. Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Jr & Bartlett JA (1999): Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrobial Agents & Chemotherapy 43:3025-3029.
31. Nowak MA, Bonhoeffer S, Shaw GM & May RM (1997) Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. Journal of Theoretical Biology 184:203-217.
32. Pereira CF & Paridaen JT (2004) Anti-HIV drug development - an overview. Current Pharmaceutical Design 10:4005-4037.
33. Perelson AS, Neumann AU, Markowitz M, Leonard JM & Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
34. Plagemann PG, Wohlhueter RM & Woffendin C (1988) Nucleoside and nucleobase transport in animal cells. Biochimica et Biophysica Acta 947:405-443.
35. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T & Wainberg MA (2003) Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Research and Human Retroviruses 19:743-753.
36. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M & Ho DD (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Medicine 6:82-85.
37. + T cells depleted? Proceedings of the National Academy of Sciences of the United States of America 99:15572-15577.
38. Rosario MC, Jacqmin P, Dorr P, van der Ryst E & Hitchcock C (2005) A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clinical Pharmacology & Therapeutics 78:508-519.
39. Rosario MC, Poland B, Sullivan J, Westby M & van der Ryst E (2006) A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. Journal of Acquired Immune Deficiency Syndrome 42:183-191.
40. Schinazi RF, Hernandez-Santiago BI & Hurwitz SJ (2006) Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Research 71:322-334.
41. Shao X (2004) Reverse transcriptase assays for the analysis of resistance to anti-HIV drugs and their mechanism of action. Ph.D. Thesis, Karolinska Instituted, Stokholm, Sweden.
42. + T cells. Nature Medicine 9:727-728.
43. Siliciano JD & Siliciano RF (2004) A long-term latent reservoir for HIV-1: discovery and clinical implications. Journal of Antimicrobial Chemotherapy 54:6-9.
44. Slob W, Janssen PH & van den Hof JM (1997) Structural identifiability of PBPK models: practical consequences for modelling strategies and study designs. Critical Reviews in Toxicology 27:261-272.
45. Solas C, Li YF, Xie MY, Sommadossi JP & Zhou XJ (1998) Intracellular nucleotides of (-)-2′,3′-deoxy-3′-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrobial Agents & Chemotherapy 42:2989-2995.
46. Sommadossi JP (1998) Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12 Suppl 3:S1-S8.
47. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD & Perelson AS (2000) Modeling plasma virus concentration during primary HIV infection. Journal of Theoretical Biology 203:285-301.
48. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL & Drusano GL (1996) A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
49. Vicini P, Gastonguay MR & Foster DM (2002) Model-based approaches to biomarker discovery and evaluation: a multidisciplinary integrated review. Critical Reviews in Biomedical Engineering 30:379-418.
50. Wahl LM & Nowak MA (2000) Adherence and drug resistance: predictions for therapy outcome. Proceedings of the Royal Scociety London: Biological Sciences 267:835-843.
51. Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS & Gerber JG (2006) Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. Journal of Pharmacokinetics & Pharmacodynamics 33:399-419.
52. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS & Gerber JG (2005) Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. Journal of Acquired Immune Deficiency Syndrome 39:272-283.
53. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M & Sommadossi JP (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial Agents & Chemotherapy 43:121-128.
54. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK & D'Argenio DZ (2006) Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrobial Agents & Chemotherapy 50:2686-2694.